Journal Article Review Epublish
PubMed: 40385063 DOI: 10.62347/ZYVY9443
Adenosine receptor subtype modulators: Insight into molecular mechanisms and their therapeutic application.
Am J Transl Res 17(4):2376-2395
Authors: Nilay Solanki, Rohinee Dodiya, Dhruvi Vejpara, Smruti Azad, Mehul Patel, Swayamprakash Patel, Umang Shah, Arun Soni, Rajesh Maheshwari, Archana Navale, Ashish Patel, Sandip Patel, Devang Sheth, Pravin Tirgar, Rachana R
Affiliations
- Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, CHARUSAT Campus Changa 388421, Gujarat, India.
- Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, CHARUSAT Campus Changa 388421, Gujarat, India. L.J. Instutite of Pharmacy, L.J. University Ahmedabad 382210, Gujarat, India.
- Department of Pharmacy, Sumandeep Vidyapeeth Vadodara 391760, Gujarat, India.
- Parul Institute of Pharmacy, Parul University Vadodara 391760, Gujarat, India.
- Department of Pharmacology, L.M. College of Pharmacy Ahmedabad 380009, Gujarat, India.
- School of Pharmacy, R.K. University Rajkot 360020, Gujarat, India.
- Department of Biotechnology, Jaypee Institute of Information Technology (JIIT) Noida 201304, Uttar Pradesh, India.
Abstract
There are four different subtypes of adenosine receptors (ARs): A1, A2A, A2B, and A3. These receptors play a role in controlling healthy and unhealthy processes related to protecting neurons, inflammation, heart health, and the growth of cancer. The A1 receptors protect neurons and the heart, while the A2A receptors play a role in treating Parkinson's disease and cancer immunotherapy. Although much less abundant than A2A receptors, they are linked to asthma and diabetes, while the A3 receptors are promising targets for autoimmune diseases and cancer. Recent research has shown that agonists and antagonists that are specific to AR can be used as medicines by changing important biological pathways. A2A antagonists, A3 agonists, and other related compounds are being tested in people with heart failure, ischemia, neurodegenerative diseases, and inflammatory disorders. However, the main problem with this is the side effects, which include heart damage, low receptor selectivity, and drug responses that are specific to certain species. In the future, scientists need to find ways to make receptor-specific ligands that work better as medicines and have fewer side effects. Current advances include selective drugs for glaucoma, asthma, and oncology, as well as new approaches for neurodegenerative diseases and chronic inflammation. With these challenges addressed, AR therapies can transform the treatment landscape of complex conditions. This review covers the molecular mechanisms, tissue-specific roles, and translational progress of AR subtypes and further advocates for ongoing innovation to optimally tailor the clinical outcome of such interventions. Therefore, unlocking the full therapeutic potential of changing the AR could lead to new ways of treating a wide range of short-term and long-term illnesses.
MeSH
Receptors, Purinergic P1, Neurons, Pharmaceutical Preparations, Heart, Neoplasms, Adenosine, Therapeutics, Asthma, Neurodegenerative Diseases